CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: These results are consistent with previous studies showing that CML-quiescent leukemic stem cells have a higher capacity to engraft in immunocompromised mice than bulk CD34+ cells [31], have stem cell properties (self-renewal), are resistant to apoptosis [32,33], are prone to genomic instability, and have impaired DNA damage responses [34,35].